Research & Innovation

Ines Dahne-Steuber, president of Spectra laboratories and Dr. Alex Ryder, Spectra's medical director discuss the opening of its new Mississippi Lab.

Real-world evidence can complement existing research in gaining new and valuable insights that improve kidney disease care with Dr. Ficociello and Dr. Winter.

The FDA has approved Korsuva (difelikefalin) for moderate to severe pruritus associated with chronic kidney disease.

While global COVID-19 data confirms that dialysis patients experienced a high rate of hospitalization and death, there has been insufficient research into many issues surrounding individuals with end stage kidney disease.

While current COVID-19 vaccines are very effective, manufacturers are developing strategies to ensure that new vaccines can keep pace with the rapid rate of mutation.

We are driving innovation and transformation in kidney care with research into regenerative medicine, organ transplant, and organ recovery.

Our Global Medical Office has created an interdisciplinary critical care team to help develop new critical care delivery improvements.

Our Global Medical Office has started a program to understand regional factors affecting performance in improving care for people with end stage kidney disease.

Our connected health platforms empower patients and clinical staff through a digital ecosystem that connects patients with healthcare professionals, medical devices, and customer service.

The Centers for Medicare and Medicaid Services (CMS) established the end stage renal disease Prospective Payment System (PPS) to facilitate beneficiary access to renal dialysis equipment.

During the COVID-19 pandemic, we deployed our Disaster Relief Team and created a pool of dialysis equipment to meet the increased demand of acute kidney injury patients.

Learn how we took the lead in developing strategies to protect patients, families, caregivers, and clinical staff from COVID-19.